TY - JOUR T1 - Depemokimab: First Approval. A1 - Lee,Arnold, Y1 - 2026/03/26/ PY - 2026/01/29/received PY - 2026/02/25/accepted PY - 2026/5/15/medline PY - 2026/3/26/pubmed PY - 2026/3/26/entrez SP - 943 EP - 948 JF - Drugs JO - Drugs VL - 86 IS - 6 N2 - Depemokimab (depemokimab-ulaa; EXDENSUR) is an anti-IL-5 antibody being developed by GSK for the treatment of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Add-on treatment with depemokimab reduced asthma-related exacerbations in patients with severe asthma with an eosinophilic phenotype, in addition to reducing the severity of nasal polyps and nasal obstruction in patients with CRSwNP. This article summarizes the milestones in the development of depemokimab leading to this first approval in the UK as an add-on maintenance treatment of asthma in adult and adolescent patients aged ≥ 12 years with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on maximum moderate-dose or high-dose inhaled corticosteroids plus another asthma controller; and as add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. SN - 1179-1950 UR - https://www.unboundmedicine.com/prime/citation/41882474/Depemokimab:_First_Approval. DB - PRIME DP - Unbound Medicine ER -